FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Cautious Hold Recommendation for Johnson & Johnson Amid ITCI Acquisition Concerns and Market Challenges
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...
WFXG23h
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
gritdaily1d
Transforming Public Healthcare: Dr. Michael D. Bradley’s Journey
The healthcare industry continues to evolve. Advancements in science and patients’ increasingly complex needs fuel this ...
MT Newswires on MSN1d
Johnson & Johnson Secures FDA Approval For Nasal Spray as Depression Monotherapy
Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration approved nasal spray Spravato as the first-ever stand-alone therapy for major depressive disorder. The product, which ...
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
News & Record5dOpinion
Allen Johnson: This could get ugly: The new hockey team is ... the Gargoyles?
“As the ownership group, our philosophy and feelings are that you guys own this team,” Kaufmann said. “It’s our job to make ...
MedPage Today5d
Online Sellers of Compounded GLP-1s Often Don't Mention Risks
Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...